Biosimilar Doubleheader: Amgen's Humira Competitor Pitching First To FDA
Arthritis Advisory Committee will preside at back-to-back biosimilar reviews for Amgen's ABP 501 and Sandoz's GP2015, which references Enbrel, in mid-July.
Arthritis Advisory Committee will preside at back-to-back biosimilar reviews for Amgen's ABP 501 and Sandoz's GP2015, which references Enbrel, in mid-July.